References
- Gay FW, Drye TJ, Dick GWA, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Brain120, 1461–1483 (1997).
- Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med.5, 170–175 (1999).
- Breij ECW, Brink BP, Veerhuis R et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol.63, 16–25 (2008).
- Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med.358, 676–688 (2008).
- McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol.50, 121–127 (2001).
- Freedman MS, Thompson EJ, Deisenhammer F et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. A consensus statement. Arch. Neurol.62, 865–870 (2005).
- Korteweg T, Tintoré M, Uitdehaag B et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol.5, 221–227 (2006).
- Villar LM, García-Barragán N, Sádaba MC et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J. Neurol. Sci.266, 34–37 (2008).
- Masjuan J, Álvarez-Cermeño JC, García-Barragán N et al. Clinically isolated syndromes. A new oligoclonal band test accurately predicts conversion to MS. Neurology66, 576–578 (2006).
- Söderström M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology50, 708–714 (1998).
- Villar LM, Masjuan J, Sádaba MC et al. Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. Arch. Neurol.62, 574–577 (2005).
- Sharief MK, Thompson EJ. The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann. Neurol.29, 147–151 (1991).
- Villar LM, Masjuan J, González-Porqué P et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology59, 555–559 (2002).
- Villar LM, Masjuan J, González-Porqué P et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol.53, 222–226 (2003).
- Perini P, Ranzato F, Calabrese M, Battistin L, Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease in multiple sclerosis. J. Neurol. Neurosug. Psychiatry77, 953–955 (2006).
- Jongen PJ, Lycklama a Nijeholt G, Lamers KJ et al. Cerebrospinal fluid IgM index correlates with cranial MRI lesion load in patients with multiple sclerosis. Eur. Neurol.58, 90–95 (2007).
- Berland R, Wortis HH. Origins and functions of B-1 cells with notes on the role of CD5. Annu. Rev. Immunol.20, 253–300 (2002).
- Boes M. Role of natural and immune IgM antibodies in immune responses. Mol. Immunol.37, 1141–1149 (2000).
- Mix E, Olsson T, Correale J et al. B cells expressing CD5 are increased in cerebrospinal fluid of patients with multiple sclerosis. Clin. Exp. Immunol.79, 21–27 (1990).
- Villar LM, Sádaba MC, Roldán E et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest.115, 187–194 (2005).
- Villar LM, N García-Barragán N, Espiño M et al. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult. Scler.14, 183–187 (2008).
- Obermeier B, Mentele R, Malotka J et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat. Med.14(6), 688–693 (2008).